Kantak, Kathleen M.Dwoskin, Linda P.2017-11-172017-11-172016-06Kathleen M. Kantak, Linda P. Dwoskin. "Necessity for research directed at stimulant type and treatment-onset age to access the impact of medication on drug abuse vulnerability in teenagers with ADHD.." Pharmacol Biochem Behav, v. 145, pp. 24 - 26.1873-5177https://hdl.handle.net/2144/25612Controversy continues regarding increased vulnerability for addiction to cocaine and other drugs of abuse in adulthood following the use of stimulant medications for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The results of recent research utilizing an animal model of ADHD strongly advocate for a closer look at this important issue in clinical populations, particularly where treatment is initiated in adolescence, and with certain ADHD medications.p. 24-26en-USAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Attention deficit hyperactivity disorderCocaineMethylphenidateSubstance use disordersAnimalsChildHumansMaleCausalityMaleAdolescenceAtomoxetineScience & technologyBehavioral sciencesLife sciences & biomedicinePharmacology & pharmacyNeurosciences & neurologyD-amphetamineSpontaneously hypertensive ratsConditioned place preferenceMethylphenidate treatmentAnimal-modelAdolescent methylphenidateAtomoxetine treatmentsAge factorsAttention deficit disorder with hyperactivityBiomedical researchCentral nervous system stimulantsProtective factorsRisk factorsSelf administrationSubstance-related disordersArticle10.1016/j.pbb.2016.03.0090000-0003-1866-9485 (Kantak, Kathleen M)